Medications That Raise Creatinine

Introduction to Medications Affecting Kidney Function

The American College of Cardiology and other guideline societies recommend monitoring serum creatinine levels when prescribing certain medications, as some can elevate serum creatinine through different mechanisms, including blocking creatinine tubular secretion or causing true renal injury 1, 2, 3, 4.

Trimethoprim blocks creatinine secretion in the proximal tubule, causing elevation without true renal dysfunction, and the Clinical Infectious Diseases journal recommends using 24-hour urine collection to estimate true creatinine clearance rather than relying on estimating formulas 1.

The British Journal of Pharmacology and Diabetes Care recommend that an expected creatinine rise of 10-30% is physiological and acceptable when using ACE inhibitors or ARBs, not pathological, and continue therapy unless creatinine rises >30% within 4 weeks of initiation or dose increase 2, 3, 4.
The Kidney International journal recommends checking serum creatinine and potassium within 2-4 weeks after starting or changing dose, and if creatinine increases <30% from baseline, continue therapy and increase dose as tolerated 4.

The British Journal of Pharmacology recommends that loop and thiazide diuretics increase risk of dehydration and renal hypoperfusion, and can precipitate prerenal azotemia through volume depletion, and NSAIDs cause genuine acute kidney injury through multiple mechanisms 2, 3, 6.

The Clinical Infectious Diseases journal recommends that cidofovir, foscarnet, amphotericin B, and pentamidine have nephrotoxic potential, and require close monitoring and dose adjustment based on creatinine clearance 1.

The Praxis Medical Insights and other guideline societies recommend that cyclosporine and immune checkpoint inhibitors can cause nephrotoxicity and immune-related nephritis, and require close monitoring 5, 7.

The Praxis Medical Insights recommends that various chemotherapy drugs, including bisphosphonates, have nephrotoxic potential and require closer monitoring 7.

The British Journal of Pharmacology recommends that calcium channel blockers, such as amlodipine, do not raise creatinine and can increase eGFR, while digoxin and hydralazine require careful monitoring due to potential nephrotoxic effects 2.

The Kidney International and Praxis Medical Insights journals recommend discontinuing or reducing dose when creatinine rise >30% above baseline within first 2 months of ACE inhibitor/ARB therapy, or when hyperkalemia ≥5.6 mmol/L develops with elevated creatinine 4, 5, 7.